Cabergoline treatment for surgery-naïve non-functioning pituitary macroadenomas

[11] Anagni M(2007)Natural history of nonfunctioning Pituitary macroadenomas followed without intervention: a retrospective cohort study Clin Endocrinol 67 938-943

[12] Reimondo G(2023)Natural history of nonfunctioning Pituitary adenomas and incidentalomas: a systematic review and metaanalysis Clin Endocrinol 98 559-566

[13] Del Monte P(2011)Treatment of hyperprolactinemia: a systematic review and Meta-analysis J Clin Endocrinol Metabolism 96 905-912

[14] Bernasconi D(2012)Dopamine receptor subtype 2 expression Profile in Nonfunctioning Pituitary adenomas and Syst Rev 1 33-746

[15] Loli P(2015) response to Cabergoline Therapy Clin Endocrinol 82 739-227

[16] Faustini-Fustini M(2019)M. B. Cabergoline in the management of residual nonfunctioning pituitary adenoma: a Single-Center, Open-Label, 2-Year randomized clinical trial Am J Clin Oncol 42 221-194

[17] Borretta G(2022)Efficacy of Cabergoline Therapy in patients with non-functioning pituitary adenomas: a single Center Clinical Experience Archives of Endocrinology and Metabolism 16 189-38

[18] Terzolo M(2013)Short-term treatment with Cabergoline Can lead to Tumor Shrinkage in patients with nonfunctioning pituitary adenomas Pituitary 14 31-undefined

[19] Losa M(2011)Comparison of three methods for the estimation of the Pituitary gland volume using magnetic resonance imaging: a Stereological Study Pituitary undefined undefined-undefined

[20] Morabito A(undefined)undefined undefined undefined undefined-undefined

[11] Anagni M(2007)Natural history of nonfunctioning Pituitary macroadenomas followed without intervention: a retrospective cohort study Clin Endocrinol 67 938-943

[12] Reimondo G(2023)Natural history of nonfunctioning Pituitary adenomas and incidentalomas: a systematic review and metaanalysis Clin Endocrinol 98 559-566

[13] Del Monte P(2011)Treatment of hyperprolactinemia: a systematic review and Meta-analysis J Clin Endocrinol Metabolism 96 905-912

[14] Bernasconi D(2012)Dopamine receptor subtype 2 expression Profile in Nonfunctioning Pituitary adenomas and Syst Rev 1 33-746

[15] Loli P(2015) response to Cabergoline Therapy Clin Endocrinol 82 739-227

[16] Faustini-Fustini M(2019)M. B. Cabergoline in the management of residual nonfunctioning pituitary adenoma: a Single-Center, Open-Label, 2-Year randomized clinical trial Am J Clin Oncol 42 221-194

[17] Borretta G(2022)Efficacy of Cabergoline Therapy in patients with non-functioning pituitary adenomas: a single Center Clinical Experience Archives of Endocrinology and Metabolism 16 189-38

[18] Terzolo M(2013)Short-term treatment with Cabergoline Can lead to Tumor Shrinkage in patients with nonfunctioning pituitary adenomas Pituitary 14 31-undefined

[19] Losa M(2011)Comparison of three methods for the estimation of the Pituitary gland volume using magnetic resonance imaging: a Stereological Study Pituitary undefined undefined-undefined

[20] Morabito A(undefined)undefined undefined undefined undefined-undefined